tiprankstipranks
Innocan Pharma’s Subsidiary Achieves Safety and Sales Milestones
Company Announcements

Innocan Pharma’s Subsidiary Achieves Safety and Sales Milestones

Story Highlights

Invest with Confidence:

InnoCan Pharma ( (TSE:INNO) ) has issued an announcement.

Innocan Pharma’s subsidiary, BI Sky Global, has completed the Human Repeated Insult Patch Test (HRIPT) for its cosmetic products, ensuring their safety. Additionally, the company has achieved a significant sales milestone by selling an average of 5,000 units per day in 2024, far exceeding the typical production quantities in the cosmetics industry. This accomplishment highlights Innocan’s robust market presence and the potential for further expansion, delivering considerable value to shareholders.

More about InnoCan Pharma

Innocan Pharma is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, it has developed a CBD-loaded liposome drug delivery platform for non-opioid pain management. In the wellness sector, Innocan markets a wide range of self-care and beauty products to promote a healthier lifestyle through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced online sales.

YTD Price Performance: -9.29%

Average Trading Volume: 11,500

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $33.87M

See more insights into INNO stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App